Lipidomic profiling in metastatic prostate cancer captures tumor metabolic rewiring and its modulation by androgen receptor–targeting therapy

Plasma lipidomics reflects key metabolic features of PCa and is profoundly impacted by AR inhibition, with prognostic relevance in patients with mCRPC. These findings support its potential as a non-invasive tool for monitoring disease activity and treatment response, and lay the groundwork for lipid-based biomarkers in mCRPC, while indicating that the lipidomic alterations observed may help inform ongoing and forthcoming research on metabolic targeting.

Authors

Institutions

Publication Details

Journal
Prostate Cancer and Prostatic Diseases
Published
2026-03-13
DOI
https://doi.org/10.1038/s41391-026-01100-z
Primary Topic
Cancer, Lipids, and Metabolism
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Lipidomic profiling in metastatic prostate cancer captures tumor metabolic rewiring and its modulation by androgen receptor–targeting therapy

Filippo Pederzoli, David M. Nanus, Salvatore Luca Burgio, Cristian Lolli et al.
Prostate Cancer and Prostatic Diseases
Cancer, Lipids, and Metabolism
article

Lipidomic profiling in metastatic prostate cancer captures tumor metabolic rewiring and its modulation by androgen receptor–targeting therapy

Filippo Pederzoli, David M. Nanus, Salvatore Luca Burgio, Cristian Lolli, Hubert Pakula, Giorgia Gurioli, Lisa M. Butler, Pier Vitale Nuzzo, Giuseppe Schepisi, Alessandra Virga, Sara Bleve, Nicole Brighi, Emilio Francesco Giunta, Francesco Ravera, Giuseppe Nicolo’ Fanelli, Silvia Rodrigues, Johannes V. Swinnen, Ugo De Giorgi, Massimo Loda
article en

Abstract

Plasma lipidomics reflects key metabolic features of PCa and is profoundly impacted by AR inhibition, with prognostic relevance in patients with mCRPC. These findings support its potential as a non-invasive tool for monitoring disease activity and treatment response, and lay the groundwork for lipid-based biomarkers in mCRPC, while indicating that the lipidomic alterations observed may help inform ongoing and forthcoming research on metabolic targeting.

Prostate Cancer and Prostatic Diseases
University of Pisa (IT), Cornell University (US), Nuffield Orthopaedic Centre (GB), Lander Institute (IL), VIB-KU Leuven Center for Cancer Biology (BE), Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IT), Dana-Farber Cancer Institute (US), South Australian Health and Medical Research Institute (AU), Centre for Cancer Biology (AU), Ospedale Vito Fazzi (IT), Istituti di Ricovero e Cura a Carattere Scientifico (IT), Azienda Ospedaliera Universitaria Pisana (IT), Weill Cornell Medicine (US), University of Genoa (IT)
U.S. Department of Defense, Prostate Cancer Foundation, Associazione Italiana per la Ricerca sul Cancro
Openalex Percentile: Top 24%
Cancer, Lipids, and Metabolism
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.